BackSanten Pharmaceutical , Ltd. Overview

Santen Pharmaceutical , Ltd. Other Current Liabilities

Track Santen Pharmaceutical , Ltd.'s other current liabilities ($51B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$50.52B
↑ 14.65% YoYΔ $6.45B vs prior year quarter

Peer trimmed avg / median

Loading

Santen Pharmaceutical , Ltd. Other Current Liabilities History

Loading

Santen Pharmaceutical , Ltd. vs. peers: Other Current Liabilities Comparison

Loading

Santen Pharmaceutical , Ltd. Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Santen Pharmaceutical , Ltd. (SNPHY) FAQ

As of the most recent data (June 2026), SNPHY shows a other current liabilities of $51B. That compares with $44B in the prior-year period — up 14.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SNPHY's other current liabilities is now $51B (was $44B) — a 14.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Santen Pharmaceutical , Ltd. is outperforming or lagging.

Tracking SNPHY's other current liabilities over time shows whether Santen Pharmaceutical , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $51B That compares with $44B in the prior-year period — up 14.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Santen Pharmaceutical , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $51B) with ownership activity and broader fundamentals.